Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034879 | Iressa Expanded Access Program (EAP) | PHASE3 | COMPLETED | - | — | — | Aug 1, 2000 | Oct 1, 2003 | Jan 4, 2013 | 626 | United States |
| Name | Type | Description |
|---|---|---|
| ZD1839 (Gefitinib) | DRUG | - |
Inclusion Criteria For inclusion in this trial, patients must fulfill all of the following criteria: * previous documented histologically or cytologically confirmed non-small cell lung cancer; * locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV)patients wh...